About Edesa

Addressing Unmet Medical Needs


Late-stage drug candidates developed by Edesa Biotech aim to help patients with limited treatment options for inflammatory and immune-related diseases

Beyond Steroids

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company founded by experts in the field of inflammation, infectious disease and gastroenterology. We are exploring new ways to treat these diseases, including alternatives to topical steroids, which can have serious side-effects. This innovative approach is made possible by proprietary technology developed to inhibit the inflammatory process at its inception rather than after inflammation has occurred.

Our lead product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. We intend to expand this technology across multiple indications, including hemorrhoids disease (HD). We also hold exclusive rights to two late-stage monoclonal antibodies, designated as EB05 and EB06, which block certain immune signaling proteins that are associated with a broad range of diseases, including infectious diseases.


We are working diligently to deliver on our mission to develop and commercialize innovative drug products that address unmet medical needs for large, underserved patient populations.

We have a number of upcoming clinical milestones and look forward completing the studies needed to advance our product candidates.

– Par Nijhawan, MD, Chief Executive Officer

Edesa Leadership

Our leadership has years of specialized expertise spanning pharmaceutical drug development, biotech research and medical care.

Executive Offices

U.S. Offices

Online Contact Form

8 + 7 =


Our executive offices are located just outside Toronto, Ontario.
Edesa Biotech, Inc.
100 Spy Court
Markham, Ontario L3R 5H6 Canada
+1 289.800.9600 (Canada)
+1 805.480.2800 (USA)

Edesa Careers

Join us in the discovery and development of a new generation of pharmaceutical drugs